News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Open Biosystems' Open Access RNAi Program Adopted by Baylor College of Medicine, University of Minnesota and Mayo Clinic

9/6/2007 8:28:04 AM

HUNTSVILLE, Ala., Sept. 6 /PRNewswire/ -- Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, announced today that three leading research institutions in North America have adopted its Open Access RNAi Program. Baylor College of Medicine, University of Minnesota and The Mayo Clinic have all recently purchased access to Open Biosystems shRNAmir and shRNA technologies for RNAi by joining the Open Access RNAi Program.

(Logo: )

Participation in the Open Access Programs allows all research laboratories within an institution access to its choice of Open Biosystems' portfolio of genome-wide resources including RNAi. The Open Access Program, unique in this field, embodies Open Biosystems' commitment to expanding access to research reagents for the life sciences community.

"The Open Access RNAi Program empowers investigators at Baylor College of Medicine with leading edge RNAi resources to support studies to unravel the complexities of the genome," said Zhou (Sunny) Songyang, Associate Professor, Biochemistry and Molecular Biology at Baylor College of Medicine. "Lentiviral shRNAmir technology from Open Biosystems will enable our researchers to harness the power of RNAi in assays and cell lines, previously limited by conventional siRNA technology, through lentiviral transduction and stable vector-based selection."

"Open Biosystems is very excited about the growing popularity of the Open Access Program for RNAi and other genomic resources. This program has fueled our mission to expand access to leading edge genomic resources within the research community," said Troy Moore, Chief Technical Officer of Open Biosystems.

Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, The RNAi Consortium (TRC) human and mouse lentiviral shRNA libraries, lentiviral inducible shRNAmir library targeting the human genome as well as RNAi collections targeting Drosophila, C. elegans and Zebrafish.

About Open Access RNAi

The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company's advanced shRNA libraries, priority technical support, and continued access to all extensions of existing libraries as well as library upgrades. In this manner, Open Biosystems supports academic research without imposing heavy financial burdens on individual labs. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide.

Complete details can be found at

About Open Biosystems

Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit

Photo: NewsCom: Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comOpen Biosystems, Inc.

CONTACT: Gwen D. Fewell, PhD of Open Biosystems Inc.,

Read at

comments powered by Disqus